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Abstract 
Objectives 
Reduced expression in immortalized cells (REIC)/dickkopf 3 (Dkk-3), a tumor 
suppressor gene, is downregulated in various cancers. We previously reported the 
tumor-inhibitory effects of the REIC/Dkk-3 gene, delivered by a conventional 
adenoviral vector (Ad-CAG-REIC,) in pancreatic cancer. Here, we developed an 
Ad-REIC vector with a novel gene expression system, termed the super gene expression 
(SGE) system, and assessed its therapeutic effects relative to those of Ad-CAG-REIC in 
pancreatic cancer cells.  
Methods 
Human pancreatic cancer cell lines ASPC1 and MIAPaCa2 were used. REIC/Dkk-3 
expression was assessed by western blot analysis. Relative cell viability and apoptotic 
effects were examined in vitro. The anti-tumor effects of Ad-REIC treatment were 
assessed in the mouse xenograft model. 
Results 
Compared with Ad-CAG-REIC, Ad-SGE-REIC elicited a significant increase in REIC 
protein expression in the cells studied. Relative to Ad-CAG-REIC, Ad-SGE-REIC 
reduced cell viability and induced apoptosis in the ASPC1 and MIAPaCa2 cell lines in 
vitro, and achieved superior tumor growth inhibition in the mouse xenograft model.  
Conclusions 
Compared with conventional Ad-REIC agents, Ad-SGE-REIC provided enhanced 
inhibitory effects against tumor growth. Our results indicate that Ad-SGE-REIC is an 
innovative therapeutic tool for pancreatic cancer. 
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Introduction 
Despite recent advances in surgery and aggressive chemotherapy, the prognosis for 
patients with pancreatic cancer remains poor.1-5 Only about 20% of patients are 
considered candidates for surgical resection at the time of diagnosis.6,7  The overall 
5-year survival rate of pancreatic cancer with gemcitabine (GEM), the standard therapy, 
is less than 5%.8 
The reduced expression in immortalized cells (REIC) gene, which is identical to 
Dickkopf-3 (Dkk-3), is a tumor suppressor gene whose expression is downregulated in 
various cancers including pancreatic cancer.9,16. In a previous study, we developed an 
adenoviral vector expressing the human REIC/Dkk-3 gene (Ad-REIC) using 
cytomegalovirus early enhancer/chicken β-actin (CAG) promoter (Ad-CAG-REIC), and 
demonstrated that the overexpression of REIC/Dkk-3 induced apoptosis in various 
cancer cell lines, as well as in pancreatic cancer cell lines.10-24 Ad-CAG-REIC induces 
cancer-selective apoptosis by stimulating the unfolded protein response, which results in 
endoplasmic reticulum (ER) stress and activation of c-Jun-NH2-kinase (JNK).12 A phase 
I/IIa study of Ad-CAG-REIC gene therapy for prostate cancer was initiated at Okayama 
University Hospital in January 2011.17 In the clinical study, direct and systemic 
anti-tumor effects induced by Ad-CAG-REIC were found to be strong enough to be 
realized as a novel therapeutic agent for castration-resistant prostate cancer.18 We 
recently developed a novel gene expression system, termed the super gene expression 
(SGE) system, and incorporated this system into the Ad-REIC vector in order to 
construct the Ad-SGE-REIC vector, for even greater therapeutic efficacy. In the 
Ad-SGE-REIC vector, three specific enhancers of human telomerase reverse 
transcriptase (hTERT), simian virus 40 (SV40), and cytomegalovirus (CMV) are placed 
in tandem after the poly A sequence to induce high expression of the inserted REIC 
gene.19 
In the current study, we assessed the therapeutic effects of Ad-SGE-REIC, in 
comparison with Ad-CAG-REIC, in two pancreatic cancer cell lines.  
 
  
Materials and methods 
Cell lines and cell culture 
The human pancreatic cancer cell lines ASPC1 and MIAPaCa2, which were selected 
because of their similar growth ratios16, were obtained from DS Pharma Biochemical 
Co., Ltd. (Osaka, Japan). ASPC1 and MIAPaCa2 were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Invitrogen, Carlsbad, CA, USA). The media were 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma, St. Louis,, 
MO, USA), 1% non-essential amino acid (Sigma), 1% sodium pyruvate (Sigma), 1% 
penicillin/streptomycin solution (Sigma), and amphotericin B (0.5 μg/mL). Cells were 
cultured at 37°C in a humidified atmosphere with 5% CO2 and 95% air.  
 
Construction and production of adenoviral vectors 
For construction of the Ad-CAG-REIC vector under the control of the CAG promoter, 
a full-length complementary DNA of REIC/Dkk-3 was integrated into a cosmid vector, 
pAxCAwt, and transferred into an adenoviral vector according to the COS-TPC method 
(Takara Bio, Shiga, Japan).12,19 In the Ad-SGE-REIC vector, hTERT, SV40, and CMV 
enhancers were placed in tandem after the poly A sequence (Fig. 1) in order to achieve 
high expression of the targeted REIC gene.19 An adenoviral vector carrying the LacZ 
gene with a CAG promoter (Ad-LacZ) was used as the control vector. The multiplicity 
of infection (MOI) was defined as the ratio of adenoviral vector-plaque forming units 
(pfu) to the number of infection-targeted cells. Plaque-based assays were used to 
determine the pfu titer (pfu/mL). Briefly, a confluent monolayer of HEK293 cells was 
infected with the virus at varying dilutions and covered with a semi-solid medium of 
agar and then the pfu titer was determined.19 
 
Western blot analysis 
Cells were plated onto six-well tissue culture plastic dishes and grown to confluence. 
The cells were then treated with Ad-CAG-REIC and Ad-SGE-REIC at the indicated 
MOI and cultured for 24 h. The cells were washed twice with cold phosphate-buffered 
saline (PBS) and lysed with sample buffer (100 mM Tris-HCl [pH 6.8], 10% glycerol, 
4% sodium dodecyl sulfate [SDS], 1% bromophenol blue, and 10% β-mercaptoethanol). 
The samples were then separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred onto a polyvinylidene fluoride (PVDF) membrane 
(Bio-Rad, Hercules, CA) for western blotting. The membranes were blocked with 
PVDF Blocking Reagent (Toyobo, Osaka, Japan) for 1 h. Then, the membranes were 
incubated for 1 h at room temperature with the following primary antibodies: human 
phospho-inositol-requiring enzyme 1α (IRE1α) (S724) (#ab48187 from Abcam, 
Cambridge, MA, USA), human phospho-stress-activated protein kinase/Jun 
aminoterminal kinase (SAPK/JNK) (Thr183/Tyr185) (#4668 from Cell Signaling 
Technology, Danvers, MA), human phospho-c-Jun (Ser73) (#3270 from Cell Signaling 
Technology), cleaved caspase-3 (Asp175) (#9661 from Cell Signaling Technology), 
human β-actin (#4967 from Cell Signaling Technology), and mouse monoclonal 
anti-human REIC/Dkk-3 antibody (produced in our laboratory). After three washes with 
Tris-buffered saline with Tween-20 (Sigma), the membranes were incubated with 
secondary antibody for 1 h at room temperature. The chemiluminescence images were 
obtained using a LAS 4000 imager (GE Healthcare Life Sciences, Pittsburgh, PA, USA). 
The signal intensity was determined using ImageQuant software (GE Healthcare Life 
Sciences, Pittsburgh, PA, USA).  
 
Cell viability assay 
The cells (2 × 105 cells) were seeded in flat-bottomed six-well plates and incubated 
for 24 h. The cells were treated with Ad-LacZ, Ad-CAG-REIC, or Ad-SGE-REIC at the 
indicated MOI in 0.5 ml of serum-free medium for 1 h. Then, 1.5 ml of fresh medium 
was added and cells were incubated for 72 h. Cell viability was assessed using 
3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, yellow tetrazole (MTT) 
to determine whether REIC/Dkk-3 expression affects cell growth in the pancreatic 
cancer cell lines ASPC1 and MIAPaCa2. Next, 200 μl of MTT was added to each well, 
and the cells were incubated for an additional 4 h at 37°C. The purple-blue formazan 
precipitate was dissolved using DMSO, and then 100 μl of the solution was added to 
flat-bottomed 96-well microplates. Cell viability was evaluated by measuring the 
absorbance at 570 nm using a microplate reader (Bio-Rad, Hercules, CA, USA). 
 
Apoptosis assay  
The cells (2 × 105 cells) were seeded in flat-bottomed six-well plates and incubated 
for 24 h. The cells were treated with Ad-LacZ, Ad-CAG-REIC or Ad-SGE-REIC at the 
indicated MOI in 0.5 ml of serum-free medium for 1 h. Then, 1.5 ml of fresh medium 
was added and the cells were incubated for 72 h. Hoechst 33342 (Wako, Tokyo, Japan) 
was added to the medium at a concentration of 2 μg/mL, and the cells were incubated in 
the dark for 10 min.15 Apoptotic cells were counted under a microscope, and the 
percentage of apoptotic cells for each sample was determined. One hundred cells were 
examined per field, and the average percentage of apoptotic cells in five different fields 
was calculated.  
 
Tumor growth assay in the mouse xenograft model 
ASPC1 cells (5.0 × 106 in 100 μL of PBS) were injected subcutaneously into the left 
flanks of 8-week-old BALB/c female mice (SLC, Hamamatsu, Japan). The mice were 
then randomly assigned to treatment groups of five animals each. One week after the 
injection of ASPC1 cells, 1.0 × 109 plaque forming units (pfu) of Ad-LacZ, 
Ad-CAG-REIC, or Ad-SGE-REIC in 100 μL of PBS were injected intra- and 
peri-tumorally. The day of adenovirus vector injection was designated day 0. 
Adenovirus vectors were injected at days 7, 14, 21, and 28 at a dose of 1.0 × 109 pfu 
/100 μL PBS/ injection. Tumor size was measured every week for 5 weeks after 
injection, and mice were sacrificed on day 35. Tumor volume was calculated using the 
following empirical formula: V = 1/2 × [(the shortest diameter) 2 × (the longest 
diameter)]. Mice were treated and cared for in strict accordance with the guidelines of 
the Institutional Animal Care and Use Committee of Okayama University Faculty of 
Medicine.  
 
Statistical analysis  
Results are presented as means ± standard error (SE). Each in vitro experiment was 
performed independently at least three times. Differences were evaluated using the 
two-tailed Student’s t-test. A p value of less than 0.05 was considered statistically 
significant. 
  
Results  
The SGE system efficiently enhanced REIC/Dkk-3 gene expression  
We developed an adenoviral vector, harboring the SGE cassette, for expression of the 
REIC/Dkk-3 gene (Fig. 1).19 In order to demonstrate the enhanced gene expression 
induced by the SGE system, we compared REIC/Dkk-3 protein expression levels in the 
transduced human pancreatic cancer cell lines (ASPC1 and MIAPaCa2) using western 
blot. It was found that Ad-SGE-REIC-transduced cells exhibited a significant increase 
(2.0-fold and 1.8-fold in ASPC1 and MIAPaCa2 cell lines, respectively) in REIC 
protein expression (Fig. 2).  
 
Ad-SGE-REIC induced apoptosis more efficiently than Ad-CAG-REIC  
Ad-CAG-REIC treatment reduced cell viability by 62.0 ± 4.5% and 39.6 ± 1.6% in 
the ASPC1 and MIAPaCa2 cell lines, respectively, in comparison with Ad-LacZ 
treatment (Fig. 3A). Ad-SGE-REIC treatment markedly reduced cell viability by 83.1 ± 
2.2% and 67.2 ± 4.2% in ASPC1 and MIAPaCa2 cells, respectively (Fig. 3A). We have 
previously found that REIC/Dkk-3 reduces cell viability by inducing apoptosis.12-16 
Therefore, apoptosis assay was performed using Hoechst 33342 dye in order to 
determine the increment of apoptotic cells following treatment with Ad-CAG-REIC 
(ASPC1; 40.4 ± 1.7%, MIAPaCa2; 38.8 ± 3.5%) and Ad-SGE-REIC (ASPC1; 73.9 ± 
1.5%, MIAPaCa2; 70.0 ± 0.6%) (Fig. 3B).  
 
Ad-SGE-REIC treatment induced apoptosis via the JNK signaling pathway  
REIC/Dkk-3 overexpression has been reported to induce apoptosis by increasing ER 
stress in pancreatic cancer cells, as well as in those of other cancer types.12-16 Therefore, 
we examined ER stress-related activation of the JNK signaling pathway. Western blot 
analysis demonstrated that phosphor-IREα, phosphor-JNK, and phosphor-c-Jun 
expression was activated by Ad-CAG-REIC treatment (Fig. 4). The expression of these 
signaling molecules was more intensely activated in cells treated with Ad-SGE-REIC 
(Fig. 4).  
 
Intratumoral Ad-SGE-REIC administration strongly inhibited tumor growth in the 
mouse xenograft model.  
In order to evaluate the therapeutic utility of Ad-SGE-REIC, we administered 
Ad-SGE-REIC intratumorally in the mouse xenograft model using ASPC1 cells. We 
found that Ad-CAG-REIC treatment suppressed tumor growth by 41.4 ± 9.8% (Fig. 5); 
however, this reduction was not statistically significant. Treatment with Ad-SGE-REIC 
resulted in stronger inhibition of tumor growth (by 60.7 ± 9.9%, p < 0.05) in 
comparison with Ad-LacZ treatment. (Fig. 5)  
 
  
Discussion 
Surgical resection is considered the only curative therapy for patients with pancreatic 
cancer; however, only 20% of patients are considered suitable candidates for surgical 
resection at the time of diagnosis.6,7 Patients with advanced pancreatic cancer exhibit a 
median survival time of approximately 6 months, and a 5-year overall survival rate of 
less than 5%.4,6,7,25,26 The prognosis of patients with pancreatic cancer is poor, and new 
therapies are required to treat such patients. 
REIC/Dkk3 is a tumor suppressor gene whose expression is downregulated in various 
cancers.9 We developed an adenoviral vector expressing the human REIC/Dkk-3 gene 
under the control of the CAG promoter.19-22 In a previous preclinical study, we found 
that the overexpression of REIC/Dkk-3, encoded by the Ad-CAG-REIC vector, induced 
apoptosis in various cancer cell lines,10-15 thereby demonstrating the potential utility of 
Ad-CAG-REIC gene therapy for the treatment of pancreatic cancer.16 However, a strong 
level of gene expression is required to achieve greater therapeutic efficacy. Therefore, in 
the present study, we developed an Ad-REIC vector incorporating the SGE system by 
placing the triple translational enhancer sequences of hTERT, SV40, and CMV 
downstream of the BGH poly A sequence (Fig. 1).19 Additionally, we assessed the 
therapeutic effects of Ad-SGE-REIC, in comparison with those of Ad-CAG-REIC, 
against pancreatic cancer. First, we assessed the efficiency of REIC protein expression 
in pancreatic cancer cells. In accordance with the findings of previous studies in other 
cancers,19 Ad-SGE-REIC induced REIC protein expression more efficiently (Fig. 2). 
Ad-CAG-REIC inhibits cell proliferation by inducing apoptosis in pancreatic cancer 
cells.16 Therefore, we performed an MTT assay and an apoptosis assay in order to 
evaluate the induction of apoptosis in Ad-SGE-REIC-treated cells. As expected, 
treatment with Ad-SGE-REIC reduced cell proliferation by inducing apoptosis with 
greater efficiency than that achieved by Ad-CAG-REIC treatment (Fig. 3).  
The overexpression of REIC/Dkk-3 encoded by the Ad-CAG-REIC vector results in 
ER-stress-mediated JNK activation, inducing apoptosis and thereby inhibiting tumor 
growth, in Ad-CAG-REIC-treated pancreatic cancer cells.12,16,24 Ad-SGE-REIC utilizes 
the same mechanism during activation of the JNK pathway and induction of ER stress, 
but with greater efficiency (Fig. 4). 
In order to confirm the therapeutic effect of Ad-SGE-REIC, we constructed a mouse 
xenograft model with ASPC1 cells. Treatment with Ad-SGE-REIC elicited stronger 
anti-tumor effects than with Ad-CAG-REIC (Fig. 5). These findings demonstrate that 
Ad-SGE-REIC-based therapy represents a promising therapeutic strategy for the 
treatment of pancreatic cancer. Several potential strategies involving gene therapy have 
been reported for the treatment of pancreatic cancer27-33; however, these have achieved 
only limited success. In a previous study, we demonstrated the therapeutic effects of 
Ad-CAG-REIC in combination with GEM.16 Treatment with Ad-CAG-REIC was found 
to inhibit tumor growth by 25.0% as compared with Ad-LacZ treatment at 28 days, 
whereas Ad-CAG-REIC inhibited tumor growth by 55.0% in combination with GEM. 
Ad-SGE-REIC treatment without GEM demonstrated an equivalent tumor-suppression 
effect (50.0 ± 13.0% at 28 days). These findings suggest that single administration of 
Ad-SGE-REIC shows potential utility as a therapeutic agent for pancreatic cancer.  
REIC-induced anticancer immune activation has been demonstrated in previous 
studies.17,24,34 We did not assess anti-cancer immunity induced by Ad-SGE-REIC, as the 
xenograft mouse model used in the present study lacks an immunocompetent innate 
immune system. Further study is necessary to assess the anti-cancer immunity induced 
by Ad-SGE-REIC using an immune-competent pancreatic cancer mouse model.  
Endoscopic ultrasound delivery (EUS) of an anti-tumor agent represents an attractive 
method for delivery of therapeutic agents in the treatment of pancreatic cancer. 
Accordingly, several clinical trials to test the efficacy of EUS-guided anti-tumor agents 
e.g. ONYX-015 and HF10, are currently ongoing.27,31,35 In addition, percutaneous 
injection therapy, which has already been developed as a safe drug delivery method for 
the treatment of liver tumors,36 represents an alternative delivery method for therapeutic 
agents in patients who have pancreatic cancer and have also developed liver metastasis. 
In the present study, we found that the Ad-SGE-REIC vector significantly enhances 
REIC/Dkk-3 protein expression and exerts a much stronger cell-killing effect in 
pancreatic cancer cells in comparison with the conventional Ad-CAG-REIC agents. 
Ad-SGE-REIC treatment additionally achieved significant therapeutic effects in 
xenograft mice with pancreatic cancer cells, indicating that Ad-SGE-REIC-based gene 
therapy represents an innovative therapeutic strategy for the treatment of patients with 
pancreatic cancer.  
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Figure Legends 
Figure 1. 
Construction of the Ad-SGE-REIC vector 
Schematic representation of the conventional gene expression system and the SGE 
system. In the conventional gene expression system, cytomegalovirus (CMV) or CMV 
early enhancer/chicken β-actin (CAG) promoter has been used to increase the gene 
expression system. In the SGE system, three specific enhancers of human telomerase 
reverse transcriptase (hTERT), simian virus 40 (SV40), and CMV are placed in tandem 
after the poly A sequence.19 
 
Figure 2. 
Western blot analysis of REIC/Dkk-3 protein expression. 
A western blot analysis was performed in order to compare REIC/Dkk-3 protein 
expression levels after transfection of ASPC1 and MIAPaCa2 human cancer cell lines 
with Ad-CAG-REIC and Ad-SGE-REIC at 30 MOI. Western blot for β-actin levels was 
performed to verify equal loading of cellular proteins. Representative blots of more than 
three independent experiments are shown. The graph below the blot shows the results of 
signal intensity analysis from three independent western blotting experiments. The 
results are presented as the mean ± standard error (SE) (n = 3). *P < 0.05.  
 
Figure 3. 
Comparison of the effects of treatment with Ad-SGE-REIC and Ad-CAG-REIC. 
(a) The cell proliferation rate was examined by MTT assay following the indicated 
treatment (no treatment, Ad-LacZ treatment, Ad-CAG-REIC treatment, or 
Ad-SGE-REIC treatment at 100 MOI for 72 h) in ASPC1 and MIAPaCa2 cells. 
(b) The rate of apoptosis was examined by Hoechst 33342 staining following the 
indicated treatment (no treatment, Ad-LacZ treatment, Ad-CAG-REIC treatment, or 
Ad-SGE-REIC treatment at 100 MOI for 72 h) in ASPC1 and MIAPaCa2 cells. 
The results are presented as the means ± standard error (SE) (n = 4). *P < 0.05. 
 
Figure 4. 
Western blot analysis to evaluate activation of signaling molecules of the JNK signaling 
pathway.  
A Western blot analysis was performed to evaluate activation of signaling molecules of 
the JNK signaling pathway by Ad-SGE-REIC in comparison with Ad-CAG-REIC. Cells 
were transfected with Ad-LacZ, Ad-CAG-REIC, and Ad-SGE-REIC at 30 MOI. Cell 
lysates were collected 48 h after transfection. The protein expression of phospho-IRE1α, 
phospho-JNK, phospho-c-Jun, and β-actin was assessed by western blot analysis using 
specific antibodies. Western blot analysis for β-actin was performed to verify equal 
loading. An analysis of the signal intensities of three independent western blot 
experiments is shown in the graph below the blot. The results are presented as the 
means ± standard error (SE) (n = 3). *P < 0.05. 
 
Figure 5. 
Effect of Ad-SGE-REIC treatment in the mouse pancreatic cancer xenograft model. 
The inoculated mice were divided into three treatment groups (Ad-LacZ, 
Ad-CAG-REIC, and Ad-SGE-REIC). The tumor volume was calculated as described in 
the Materials and Methods section. The results are presented as the means ± standard 
error (SE) (n = 5). *P < 0.05. 
 






